Clinical trials: Pulmonary Artery Hypertension
Healthy Volunteers, Pulmonary Arterial Hypertension
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)
- Trial name
- NCT06649110
- Testing
- LTP
- Where
- 87 sites in United States, Argentina and 16 more
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Artery Hypertension
Trimetazidine in Pulmonary Artery Hypertension
Pulmonary artery hypertension (PAH) is a chronic and progressive disease that affects 15 persons per million. Although current therapy has improve disease prognosis, PAH still has a poor survival, with a median survival of 2.8…
- Trial name
- NCT02102672
- Testing
- Trimetazidine
- Where
- Chile
- Volunteers
- 25 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Pulmonary Hypertension
Wave Intensity Analysis in the Pulmonary Artery
The mechanism governing how blood flows from the heart to the lungs depends on many factors including the pumping function of the right ventricle, properties of the arteries that carry the blood from the right ventricle to the…
- Trial name
- NCT01972009
- Testing
- Cardiac catheterisation
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Pulmonary Arterial Hypertension PAH
Study of Intravenous ZMA001 in Healthy Subjects
Background: A number of diseases can cause a type of lung injury called pulmonary arterial hypertension (PAH). Most people who develop PAH do not survive more than a few years. A new study drug (ZMA001) may help.
- Trial name
- NCT05967299
- Testing
- ZMA001 (BC-NKA-20008)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Arterial Hypertension
TReatment Of Pulmonary HYpertension 1 Study
The objective of this study is to assess the safety, performance and initial effectiveness of the TIVUS™ System when used for pulmonary artery denervation through subjective and objective change in clinical parameters and…
- Trial name
- TROPHY (NCT02516722)
- Testing
- Therapeutic Intra-Vascular UltraSound (TIVUS™) System
- Where
- 4 sites in Belgium, Israel and 1 more
- Volunteers
- 15 people
- Sponsor
- SoniVie Inc.
Pulmonary Arterial Hypertension, Physical Inactivity
Physical Activity and Various Aspects of Quality of Life in Patients With Pulmonary Arterial Hypertension (Ph-PAH)
Evaluate whether education, a simple doctor's recommendation to increase physical activity in inactive patients, and self-monitoring of physical activity using a pedometer were effective and beneficial for patients with pulmonary…
- Trial name
- PhA-PAH (NCT06312111)
- Testing
- recommendation to increase physical activity
- Where
- Poland
- Volunteers
- 48 people
- Sponsor
- Centre of Postgraduate Medical Education
Idiopathic Pulmonary Arterial Hypertension
Empagliflozin in Pulmonary Arterial Hypertension
The aim of the study is to determine whether conducting a randomized placebo-controlled clinical trial is feasible, safe for the patient and whether the treatment is well tolerated in patients with idiopathic pulmonary arterial…
- Trial name
- Emphower PoC (NCT05493371)
- Testing
- Empagliflozin 10 MG
- Where
- Netherlands
- Volunteers
- 8 people
- Sponsor
- Amsterdam UMC, location VUmc
Pulmonary Arterial Hypertension, Systemic Sclerosis
Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)
Aim: to investigate the role of inflammation and auto-immunity in pulmonary arterial hypertension by using the profile of volatile organic compounds.
- Conditions
- Pulmonary Arterial Hypertension, Systemic Sclerosis, Systemic Lupus
- Trial name
- VOC-PAH (NCT03819777)
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Maastricht University Medical Center
Myeloproliferative Disorder, Myelodysplastic Syndromes
Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases
Myelodysplastic and myeloproliferative Disease represent conditions with increased risk for pulmonary hypertension. However, the exact prevalence of pulmonary hypertension in these conditions is not known.
- Conditions
- Myeloproliferative Disorder, Myelodysplastic Syndromes, Pulmonary Hypertension
- Trial name
- NCT00909467
- Testing
- echocardiography, right heart catheterisation
- Where
- Austria
- Volunteers
- 86 people
- Sponsor
- Medical University of Graz
Scleroderma, Diffuse, Scleroderma, Systemic
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary…
- Conditions
- Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic
- Trial name
- NCT02682511
- Testing
- Oral Ifetroban
- Where
- 13 sites in United States, India
- Volunteers
- 34 people
- Sponsor
- Cumberland Pharmaceuticals
Pulmonary Arterial Hypertension
Exercise Capacity Muscle Oxygenation and Arterial Stiffness in Children With Pulmonary Arterial Hypertension
The primary aim is to evaluate pulmonary function, respiratory muscle strength, upper and lower extremity exercise capacity, muscle oxygenation, dyspnea, peripheral muscle strength, arterial stiffness, physical activity level and…
- Trial name
- NCT06454838
- Where
- Turkey (Türkiye)
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Gazi University
Congenital Heart Disease, Pulmonary Arterial Hypertension
Biomarkers in Pediatric Congenital Heart Disease and PAH
Nowadays, biomarkers are broadly used in clinical practice. Blood-derived biomarkers fulfil an important role in the field of cardiology. However, most biomarkers have been investigated for adult left ventricular disease.
- Trial name
- NCT04130243
- Testing
- Blood test
- Where
- Netherlands
- Volunteers
- 380 people
- Sponsor
- University Medical Center Groningen
Pulmonary Arterial Hypertension
A nUtrition and Lifestyle Intervention in Patients With Pulmonary Arterial HypertensIon
Rationale: Nutrition and lifestyle interventions are currently not implemented in usual clinical care of PAH-patients. Mainly because there is little known on the relation between pathology, nutrition and lifestyle.
- Trial name
- UPHILL (NCT05318950)
- Testing
- E-learning, Diet
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Amsterdam UMC, location VUmc
Pulmonary Arterial Hypertension
[18F]FES PET/CT in PAH
In this study positron emission tomography (PET/CT) imaging will be used to evaluate evaluation of estrogen receptor heterogeneity and functionality in Pulmonary Arterial Hypertension (PAH) using the investigational radiotracer…
- Trial name
- NCT02899533
- Testing
- [18F] FES
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pennsylvania
Pulmonary Arterial Hypertension
Pulmonary Hypertension: Intensification and Personalisation of Combination Rx
The goal of this clinical trial is to evaluate the capacity of implantable/remote technology for early evaluation of drug therapies in patients with pulmonary arterial hypertension (PAH).
- Trial name
- PHoenix (NCT05825417)
- Testing
- Selexipag, Riociguat, CardioMEMS pulmonary artery pressure monitor
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
High Altitude, Healthy
Assessment of Total Pulmonary Resistance sPAP/CO Between Sea Level LA vs. High Altitude HA After Re-ascent in Healthy Individuals
To study the effect of a re-ascent after a one-week stay at sea level (after prior descent from 2850m) to high altitude (Quito Ecuador: 2850m) on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in healthy…
- Conditions
- High Altitude, Healthy, Healthy Adult, High Altitude Effects
- Trial name
- NCT07804589
- Testing
- Re-Ascent from sea level to 2850m
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Arterial Hypertension
Efficacy of Ventavis Used in Real-life Setting.
This is a registry of patients diagnosed with pulmonary arterial hypertension, scheduled for treatment with Ventavis. Typical clinical measures and quality of life will be prospectively followed in 12 months period.
- Trial name
- SPHERA (NCT01355380)
- Testing
- Inhaled iloprost (Ventavis, BAYQ6256)
- Where
- Poland
- Volunteers
- 55 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Effects of DHEA in Pulmonary Hypertension
The goal of this crossover trial is to determine whether the study drug dehydroepiandrosterone (DHEA) improves right ventricular longitudinal strain measured by cardiac magnetic resonance imaging at 18 weeks AND 40 weeks compared…
- Trial name
- EDIPHY (NCT03648385)
- Testing
- DHEA tablet
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Rhode Island Hospital
Pulmonary Hypertension, Metal Poison
Study Roles of Heavy Metals and Essential Metal Dyshomeostasis in Pulmonary Arterial Hypertension Patients
Investigators plan to recruit 50 PAH patients from UofL PAH Clinic, with various degrees of severity (25 intermediate risk patients and 20 high risk patients) and 10 age and gender matched controls.
- Trial name
- NCT04756076
- Testing
- Metal level measurements
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Jiapeng Huang
Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)
This is a randomized, double-blind, multi-center, placebo-controlled dose-ranging clinical trial of two IkT-001Pro doses in patients with PAH designed to assess safety, tolerability and efficacy.
- Trial name
- NCT06643143
- Testing
- IkT-001Pro
- Sponsor
- Inhibikase Therapeutics